- The FDA has reviewed and cleared Bio-Path Holdings' (NASDAQ:BPTH) IND application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate.
- An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients.
- Shares are up 15% premarket.
FDA clears Bio-Path's IND for BP1002
Recommended For You
More Trending News
About BPTH Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BPTH | - | - |
Bio-Path Holdings, Inc. |